Sherwin-Williams Company (The)NYSE: SHW
Materials · Specialty Chemicals
$317.83
-1.18%
Vol: 990K
Research Digest
Friday, May 1, 2026
Sherwin-Williams Q1 2026 beats but warns of demand softness; reduces guidance to $11.50-$11.90 EPS.
Sherwin-Williams Q1 2026 EPS $2.35 (vs $2.27 est) and revenue $5.67B (vs $5.56B est), consolidated net sales +6.8%. Despite earnings beat, issued cautious FY adjusted EPS guidance of $11.50-$11.90 (vs $11.74 consensus), citing heightened global uncertainty and persistent demand softness. Stock fell 1.98%. Morgan Stanley reiterated Overweight with $385 PT, Mizuho raised PT from $371 to $396, Wells Fargo reduced PT from $365 to $350 with Equal Weight. Management warned of rising material costs amid geopolitical tensions.
Previous Market Intelligence
13 daysApr 30Sherwin-Williams beats Q1 earnings with 6.8% sales growth; Wells Fargo downgrades to Equal Weight due to Iran-driven material costs.Mixed▶
Sherwin-Williams reported strong Q1 2026 results on April 28 with consolidated net sales of $5.67 billion (up 6.8%) and adjusted EPS of $2.35 (up 4.4%), beating estimates. Automotive refinish posted double-digit growth and the company reaffirmed 2026 guidance. However, Wells Fargo downgraded the stock from Outperform to Equal Weight, reducing the price target from $365 to $350 due to rising raw material costs from the Iran conflict. Morgan Stanley maintained Overweight with a $385 PT. Management cited ongoing demand softness and rising raw material costs, expecting little to no recovery in most end markets in 2026.
Apr 16Wells Fargo downgrades SHW to Equal Weight; cites raw materials cost pressure from Iran tensionsNegative▶
Sherwin-Williams downgraded by Wells Fargo to Equal Weight from Overweight with $365 target (down from $410) on April 10, citing rising raw materials costs due to geopolitical tensions. Company maintains 47-year dividend streak but faces macro headwinds and valuation concerns. Q4 revenue grew 5.6% YoY, beating EBITDA estimates. Earnings April 28.
Apr 15Sherwin-Williams Q1 2026 earnings scheduled for April 28; analyst consensus remains Buy despite recent price target cuts.Mixed▶
Sherwin-Williams will announce Q1 2026 financial results before market open on April 28 with consensus expecting EPS of $2.34. The company issued FY2026 adjusted EPS guidance of $11.50-$11.90. UBS lowered price target from $420 to $380 on April 2, and Citigroup cut from $410 to $385. The 11 analysts covering SHW maintain a Buy consensus with average price target of $384.64. Sherwin-Williams continues its 47-year consecutive annual dividend increase streak.
Apr 14Sherwin-Williams reports Q1 2026 earnings April 28; Wells Fargo downgrades to Equal Weight amid market challenges.Mixed▶
Sherwin-Williams will announce Q1 2026 results on April 28. Analysts expect Q1 EPS of $2.34 (up 4% YoY). Wells Fargo downgraded to Equal Weight (April 10) with $365 target; UBS cut to $380; Citigroup lowered to $385. 11 analysts maintain Buy consensus with $384.64 average target (20.96% upside). Stock at ~$330.
Apr 13Wells Fargo downgrades Sherwin-Williams to Equal-Weight on sluggish sales growth; Q1 2026 earnings April 28.Mixed▶
Wells Fargo downgraded Sherwin-Williams from Overweight to Equal-Weight on April 10, lowering price target from $410 to $365, citing sluggish sales growth. Analysts expect Q1 2026 EPS of $2.34, up 4% YoY. Company maintains a 47-year dividend increase streak but faces macroeconomic headwinds and valuation concerns. Earnings release scheduled April 28.
Apr 10Sherwin-Williams faces shareholder governance proposal to lower special meeting threshold at April 22 annual meeting.Mixed▶
Shareholder John Chevedden proposed lowering ownership threshold for calling special meetings; board opposes at April 22 meeting. Q4 2025 revenue $5.60B (+5.6% YoY) beat estimates but FY EPS guidance missed. Stock at $332.20, up 1.33%. Buy ratings from 16 analysts with average 12-month target of $382.29. Q1 2026 earnings due April 28, 2026.
Apr 9Sherwin-Williams stock rises 6.95% in 24 hours as Q4 earnings beat despite sluggish sales growth concerns.Positive▶
Sherwin-Williams delivered strong Q4 2025 results with $5.60B revenue (up 5.6% YoY), exceeding estimates by 0.8%, including first full quarter of Suvinil acquisition. SHW stock increased 6.95% in past 24 hours, up 3.82% weekly and 3.47% monthly, though full-year EPS guidance missed analyst expectations. Company maintains 47-year dividend increase streak but faces questions about sustainability amid macroeconomic challenges and sluggish sales growth amid high valuation concerns. Analysts remain bullish with average Buy rating from 11 analysts targeting $384.64 (23.34% upside). Next earnings report April 28, 2026.
Apr 8Sherwin-Williams posts earnings beat but disappoints with guidanceNeutral▶
Sherwin-Williams reported strong Q4 earnings with a 5.6% year-on-year revenue increase and EBITDA beat, yet full-year EPS guidance fell short of expectations. The stock declined 2.36% in the last 24 hours as investors balance the strong execution against macroeconomic headwinds. The company maintains a 47-year dividend increase streak.
Apr 7Sherwin-Williams reports Q4 revenues up 5.6% but faces margin squeeze and analyst cautionMixed▶
Sherwin-Williams delivered strong Q4 with revenues of $5.60B, up 5.6% YoY, exceeding analyst expectations by 0.8%, including first full quarter of Suvinil acquisition. However, stock down 9% since reporting amid modest earnings growth and guidance concerns. Stock currently $318. Jefferies maintains Hold rating citing margin squeeze. 16 analysts recommend Buy with $382.29 average 12-month target.
Apr 6Sherwin-Williams Q1 earnings scheduled for April 28; Q4 double-beat with strong dividend recordPositive▶
Sherwin-Williams delivered a strong Q4 with EPS of $2.23 and revenue of $5.6B, both exceeding consensus. Full-year 2025 net sales were $23.57 billion, up 2.1% year-over-year. The company declared a regular quarterly dividend of $0.80 per share, continuing a 47-year streak of consecutive annual dividend increases. Upcoming Q1 2026 results release set for April 28, 2026. Analysts rate the stock as "Buy" with an average 12-month price target of $384.64, representing 20.96% upside potential.
Apr 3UBS cuts price target to $380 from $420 on valuation concerns, though maintains buy rating; Zacks upgrades to hold.Mixed▶
On April 2, 2026, UBS Group downgraded its price target for Sherwin-Williams from $420 to $380, citing concerns about sluggish sales growth and valuation pressures despite strong Q4 earnings. Zacks Research upgraded SHW from strong sell to hold. Q4 2025 EPS of $2.23 (beating $2.16 forecast) and revenue of $5.6 billion. 2026 projects low to mid-single-digit sales growth with diluted EPS guidance of $10.70-$11.10.
Apr 2Sherwin Williams Q1 earnings scheduled for April 28 with analyst consensus rating of Buy at $385.50 price target.Neutral▶
Sherwin Williams will announce Q1 2026 results on April 28, 2026, with a conference call at 10:00 a.m. EDT. The company maintains a 47-year streak of consecutive dividend increases. Recent performance shows mixed sentiment as the company faces sluggish sales growth despite maintaining strong dividend discipline, though analysts question sustainability amid macroeconomic headwinds. No significant new material developments in the last 48 hours.
Apr 1Sherwin-Williams raised quarterly dividend to $0.80 per share, maintaining a 47-year dividend increase streak amid weak 2026 guidance.Mixed▶
Sherwin-Williams reported strong Q4 2025 results with record sales and adjusted EPS of $2.23. The company raised its quarterly dividend but issued cautious guidance for 2026, anticipating low- to mid-single-digit sales growth. 16 out of 17 analysts recommend a buy rating.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| SHWSHERWIN | $317.83 | -1.18% | +1.6% | 24.2x | 1.27 | $79.3B |
| ECLECOLAB | $259.78 | -0.31% | -2.4% | 27.2x | 1.02 | $73.6B |
| PPGPPG | $107.42 | -1.00% | +4.5% | 12.4x | 1.16 | $24.3B |
| LYBLYONDELLBASELL | $74.91 | +0.42% | -5.1% | 13.1x | 0.44 | $24.1B |
| ALBALBEMARLE | $193.55 | -1.60% | +13.7% | 21.8x | 1.43 | $23.2B |
| DDDUPONT | $46.29 | +1.38% | +0.2% | 17.9x | 1.12 | $18.7B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.